Pfizer (PFE) has put fresh clinical and regulatory news in focus, including new European approval for hemophilia treatment HYMPAVZI, promising pneumococcal vaccine data, and an oncology research tie up with Sarah Cannon Research Institute.

Against this backdrop of fresh clinical and partnership news, Pfizer’s shares trade at US$25.90, with a 7 day share price return of 2.25% but a 30 day share price return down 4.07%, while the 1 year total shareholder return of 18.82% contrasts with weaker 3 and 5 year total shareholder returns. This suggests that recent momentum has improved from a softer multi year picture as investors reassess pipeline progress and patent risk.

If you are looking beyond large pharma for what could shape the next leg of healthcare, this is a good moment to scan 34 healthcare AI stocks

With Pfizer trading at US$25.90, sitting on a mixed track record of recent gains and longer term share price declines plus a high dividend yield, the key question is simple: is this reset an undervalued opportunity, or is the market already pricing in whatever future growth the refreshed pipeline delivers?

Most Popular Narrative: 15.4% Undervalued

Pfizer’s most followed narrative pegs fair value at $30.62, comfortably above the last close at $25.90, which is driving fresh interest in the stock.

I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines. This should keep revenue flat, possibly growing in low to mid single digits in an optimistic scenario. Also, I think they will continue to release many new products that are already in phase 3 of research. If they're able to do this, maintain a 70% operational margin, increase profitability (by cutting costs, expanding margins etc.) and paying down debt, in the long term i see good anual returns (low double digits) from current stock price levels. There is risk for investors in the meantime! Pfizers transition needs to happen fast otherwise Pfizer will have to borrow more money due to the capital nature of the bussiness. Of course, this is not a capital light industry and pfizer debt levels are allready very high when we compare them with free cash flow to equity. Also, there is a risk of a dividend cut wich would harm investors. Investors should be aware of these risks in this turnaround play.

The fair value hinges on oncology depth, product launches already in late stage trials, and ambitious margin assumptions. Curious how those pieces fit together into $30.62.

Result: Fair Value of $30.62 (UNDERVALUED)

However, investors still face real execution risk related to debt levels and any future dividend cut, which could quickly challenge the 15.4% undervaluation narrative.

Next Steps

With sentiment split between concern about risks and optimism about potential rewards, this is a good time to look at the data and decide where you stand; start by weighing the 1 key reward and 4 important warning signs

Looking for more investment ideas?

If you stop with Pfizer, you could miss other opportunities that fit your style. Take a few minutes to broaden your watchlist using these focused stock lists.

• Target reliable cash generators by scanning companies highlighted in 10 dividend fortresses.
• Spot potential bargains before they become crowded trades by reviewing the 48 high quality undervalued stocks.
• Prioritize resilience and aim for more peace of mind by checking stocks in the 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.